ArticleJournal of managed care & specialty pharmacy2026
The burden of heart failure in the United States: Medical costs and health-related quality of life.
Article in Journal of managed care & specialty pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure (HF) is a leading cause of morbidity, mortality, and health care utilization in the United States. Its burden is expected to increase with population aging and the growing prevalence of diabetes, yet comprehensive estimates of health care costs and health-related quality of life (HRQoL) stratified by age and diabetes status-2 key drivers of HF risk and resource use-remain limited.
objectiveTo quantify the economic burden and HRQoL impact of HF in the United States, stratified by age and diabetes status.
methodsUsing a micro-level, bottom-up prevalence-based approach from a payer perspective, we analyzed health care costs from the Optum Research Database. HF prevalence and HRQoL via EuroQol 5-Dimensions and Healthy Days instruments were estimated using the National Health and Nutrition Examination Survey.
resultsThe average annual direct health care cost per patient with HF was approximately $31,464 at baseline, rising to $45,893 in the first year after diagnosis before stabilizing around $37,500 annually. Inpatient and emergency care accounted for the largest cost share. Extrapolating at the national level, expenditures exceeded $227 billion at baseline and peaked at $332 billion in the year following an HF hospitalization. Individuals without diabetes had the highest quality-adjusted life-years (QALYs) and lowest costs, whereas patients with type 1 diabetes had the lowest QALYs and highest costs. Patients with type 2 diabetes represented the largest subgroup with intermediate QALYs but substantial costs.
conclusionsHF imposes a significant, sustained economic and quality-of-life burden, highlighting the need for targeted management strategies, especially for older adults and those with diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.